Teva Pharma (TEVA) volatility flat into Mylan (MYL) granted FDA approval of Copaxone

Teva (NYSE: TEVA) October weekly call option implied volatility is at 40, October is at 41, November is at 47; compared to its 52-week range of 24 to 61 into Mylan (Nasdaq: MYL) was granted FDA approval of the first generic for Copaxone.

You May Also Be Interested In

• UAE Says Situation Currently Safe After Potential Threat Alert
• Apple (AAPL) call put ratio 1.6 calls to 1 put as share price down 5.1%
• Synaptics (SYNA) call put ratio 2.8 calls to 1 put into On Semi (ON) acquiring in a $7B all-stock transaction